Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…Abstract Number: 0834 • ACR Convergence 2024
Evolution of Lung Inflammation in a Mouse Model of Chronic/Recurrent Macrophage Activation Syndrome
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) is a life-threatening complication and associated in >80% of cases with macrophage activation syndrome (MAS); however, the…Abstract Number: 1144 • ACR Convergence 2024
Autoantibody and Radiological Profiles as Prognostic Indicators in Idiopathic Inflammatory Myopathies: Insights into Mortality and Interstitial Lung Disease Development
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) constitute a diverse group of acquired muscle disorders, often involving multiple organs such as the skin, heart, and lungs.…Abstract Number: 1590 • ACR Convergence 2024
Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…Abstract Number: 1976 • ACR Convergence 2024
Artificial Intelligence Analysis of HRCT Images Reflects Pulmonary Involvement in Systemic Sclerosis Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and morbidity in systemic sclerosis (SSc) patients. Current functional, imaging, and clinical measures of…Abstract Number: 2443 • ACR Convergence 2024
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Background/Purpose: To evaluate clinical associations of anti-Th/To antibodies in SSc patients in a multicentre international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension…Abstract Number: 0317 • ACR Convergence 2024
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…Abstract Number: 0853 • ACR Convergence 2024
Lung Ultrasound in Rheumatoid Arthritis and Systemic Sclerosis: Accuracy of B-line and Pleural Assessment
Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA) and systemic sclerosis (SSc). Although computerized tomography (CT) is considered…Abstract Number: 1153 • ACR Convergence 2024
Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Background/Purpose: In recent years, connective tissue diseases (CTDs) have been increasingly recognized as a significant underlying pathology of interstitial lung diseases (ILDs). Amongst CTDs, idiopathic…Abstract Number: 1608 • ACR Convergence 2024
Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes
Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…Abstract Number: 1990 • ACR Convergence 2024
Human Umbilical Cord Mesenchymal Stem Cell-derived Microvesicles Alleviate Pulmonary Fibrosis by Inhibiting Monocyte-macrophage Migration Through ERK1/2 Signaling-mediated Suppression of CCL2 Expression
Background/Purpose: Pulmonary fibrosis (PF) is a disease with high morbidity and mortality rates, but effective treatment options extremely limited. Mesenchymal stem cells (MSCs) and their…Abstract Number: 2451 • ACR Convergence 2024
Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Pulmonary function tests (PFTs) can serve as useful surrogate measures…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 39
- Next Page »